Table1.
Summary of clinicopathological features of the studied prostate cancer cohort at the time of diagnosis, patient demographics of the studied prostate cancer cohort, and cases with recurrence and no recurrence within the studied prostate cancer cohort
| Clinicopathological cohort, n (%) | |||
|---|---|---|---|
| Recurrence | Nonrecurrence | Total | |
| No. of patients | 22 (31.4) | 48 (68.6) | 70 |
| Gleason score | |||
| 6 | 1 (11.1) | 8 (88.9) | 9 (12.9) |
| 7 (3 + 4) | 3 (17.7) | 14 (82.3) | 17 (24.3) |
| 7 (4 + 3) | 3 (16.7) | 15 (83.3) | 18 (25.7) |
| 8 | 8 (47.1) | 9 (52.9) | 17 (24.3) |
| 9 | 7 (77.8) | 2 (22.2) | 9 (12.9) |
| Primary tumor stage | |||
| pT2 | 2 (6.9) | 27 (93.1) | 29 (41.4) |
| pT3a | 15 (48.4) | 16 (51.6) | 31 (44.3) |
| pT3b | 5 (62.5) | 3 (37.5) | 8 (11.4) |
| Unknown | 0 (0) | 2 (100) | 2 (2.9) |
| Lymph node | |||
| Positive | 0 (0) | 1 (100) | 1 (1.4) |
| Negative | 22 (31.9) | 47 (68.1) | 69 (98.6) |
| Surgical margin | |||
| Positive | 20 (51.3) | 19 (48.7) | 39 (55.7) |
| Negative | 2 (6.4) | 29 (93.5) | 31 (44.3) |
| Presurgical PSA, ng/mL | |||
| 0–10 | 12 (25.0) | 36 (75.0) | 48 (68.6) |
| 10–20 | 6 (37.5) | 10 (62.5) | 16 (22.9) |
| 20–30 | 2 (66.7) | 1 (33.3) | 3 (4.3) |
| 30–40 | 2 (66.7) | 1 (33.3) | 3 (4.3) |
| Patient demographics, mean ± SD | |||
| Variable | Recurrence | Nonrecurrence | |
| Age, yr | 59.04 ± 6.57 | 58.82 ± 5.80 | |
| Gland weight, g | 51.94 ± 14.90 | 56.19 ± 21.38 | |
| PSA, ng/ml | 8.29 ± 5.29 | 13.17 ± 10.15 | |
| PSAD, ng/ml/g | 0.17 ± 0.11 | 0.25 ± 0.20 | |
| Time to event, yr | 5.06 ± 4.50 | 3.82 ± 2.36 | |
| Outcomes for recurrence and no recurrence, n | |||
| Recurrence | 22 | ||
| Died from prostate cancer | 2 | ||
| Died from another cause with recurrence | 1 | ||
| Distant metastasis | 1 | ||
| Increase in PSA (>0.2 ng/ml) | 14 | ||
| Local recurrence | 1 | ||
| Local recurrence and distant metastasis | 3 | ||
| No recurrence | 48 | ||
| Died from noncancer cause | 1 | ||
| No recurrence | 47 | ||
PSA = prostate-specific antigen; PSAD = prostate-specific antigen density; SD = standard deviation.